---
figid: PMC9465188__JCMM-26-4745-g001
figtitle: Recent advances in the therapeutic efficacy of hepatocyte growth factor
  gene‐modified mesenchymal stem cells in multiple disease settings
organisms:
- Mus musculus
- Rattus norvegicus
- Adenoviridae
- Adeno-associated virus
- Homo sapiens
organisms_ner:
- Rattus norvegicus
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC9465188
filename: JCMM-26-4745-g001.jpg
figlink: /pmc/articles/PMC9465188/figure/jcmm17497-fig-0001/
number: F1
caption: Main mechanisms of HGF/MSC therapy. HGF/MSCs were adopted in treatment for
  a variety of diseases, including ischaemic, heart, lung, liver, urinary system,
  bone and immune‐related diseases. (1) HGF/MSC promote cell migration and engraftment,
  in which SDF‐1α/CXCR‐4 axis and ERK1/2 signalling pathway were involved. (2) HGF/MSCs
  promote cell–cell connection restoration and soft tissue re‐epithelialization. (3)
  HGF/MSCs promote angiogenesis and neurogenesis. (4) HGF/MSCs promote anti‐fibrosis
  effect. (5) HGF/MSCs promote anti‐inflammatory effect. They can deactivate Th1 and
  Th17 cells and activate Treg cells. (6) HGF/MSCs promote anti‐apoptosis effect.
  (7) HGF/MSCs promote anti‐oxidation effect. Bcl, B‐cell lymphoma; COL, collagen;
  Cx43, connexin 43; CXCR4, chemokine (C‐X‐C motif) receptor 4; ERK1/2, extracellular
  regulated protein kinases 1/2; FGF, fibroblast growth factor; FN, fibronectin; GSH,
  antioxidant glutathione; ICAM, intercellular adhesion molecule; IFN‐γ, interferon
  gamma; IL, interleukin; MDA, antioxidant metabolite malondialdehyde; MMP, matrix
  metalloproteinase; S1PR1, sphingosine 1‐phosphate receptors 1; SDF‐1, stromal cell‐derived
  factor‐1; Smad, small mothers against decapentaplegic; SOD, superoxide dismutase;
  TGF‐β, transforming growth factor‐beta; Th1, T helper 1 cell; Th17, interleukin
  17 (IL‐17)‐secreting helper T; TNF‐α, tumour necrosis factor alpha; Treg, regulatory
  T cell; VCAM, vascular cell adhesion protein; VEGF, vascular endothelial growth
  factor; ZO‐1, zonula occludens‐1; α‐SMA, alpha‐smooth muscle Actin; γ‐GCS, gama
  glutamylcysteine synthetase.
papertitle: Recent advances in the therapeutic efficacy of hepatocyte growth factor
  gene‐modified mesenchymal stem cells in multiple disease settings.
reftext: Hong‐fang Meng, et al. J Cell Mol Med. 2022 Sep;26(18):4745-4755.
year: '2022'
doi: 10.1111/jcmm.17497
journal_title: Journal of Cellular and Molecular Medicine
journal_nlm_ta: J Cell Mol Med
publisher_name: John Wiley and Sons Inc.
keywords: clinical application | hepatocyte growth factor (HGF) | HGF gene‐modified
  MSCs (HGF/MSCs) | mesenchymal stem cells (MSCs) | therapeutic efficacy
automl_pathway: 0.8885644
figid_alias: PMC9465188__F1
figtype: Figure
redirect_from: /figures/PMC9465188__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9465188__JCMM-26-4745-g001.html
  '@type': Dataset
  description: Main mechanisms of HGF/MSC therapy. HGF/MSCs were adopted in treatment
    for a variety of diseases, including ischaemic, heart, lung, liver, urinary system,
    bone and immune‐related diseases. (1) HGF/MSC promote cell migration and engraftment,
    in which SDF‐1α/CXCR‐4 axis and ERK1/2 signalling pathway were involved. (2) HGF/MSCs
    promote cell–cell connection restoration and soft tissue re‐epithelialization.
    (3) HGF/MSCs promote angiogenesis and neurogenesis. (4) HGF/MSCs promote anti‐fibrosis
    effect. (5) HGF/MSCs promote anti‐inflammatory effect. They can deactivate Th1
    and Th17 cells and activate Treg cells. (6) HGF/MSCs promote anti‐apoptosis effect.
    (7) HGF/MSCs promote anti‐oxidation effect. Bcl, B‐cell lymphoma; COL, collagen;
    Cx43, connexin 43; CXCR4, chemokine (C‐X‐C motif) receptor 4; ERK1/2, extracellular
    regulated protein kinases 1/2; FGF, fibroblast growth factor; FN, fibronectin;
    GSH, antioxidant glutathione; ICAM, intercellular adhesion molecule; IFN‐γ, interferon
    gamma; IL, interleukin; MDA, antioxidant metabolite malondialdehyde; MMP, matrix
    metalloproteinase; S1PR1, sphingosine 1‐phosphate receptors 1; SDF‐1, stromal
    cell‐derived factor‐1; Smad, small mothers against decapentaplegic; SOD, superoxide
    dismutase; TGF‐β, transforming growth factor‐beta; Th1, T helper 1 cell; Th17,
    interleukin 17 (IL‐17)‐secreting helper T; TNF‐α, tumour necrosis factor alpha;
    Treg, regulatory T cell; VCAM, vascular cell adhesion protein; VEGF, vascular
    endothelial growth factor; ZO‐1, zonula occludens‐1; α‐SMA, alpha‐smooth muscle
    Actin; γ‐GCS, gama glutamylcysteine synthetase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tjp1
  - Gja1
  - Hgf
  - Fgf2
  - Vegfa
  - Vcam1
  - Mapk3
  - Mapk1
  - Tgfb1
  - COX1
  - Cxcr4
  - Cxcl12
  - Il13
  - Il6
  - Il17a
  - Tnf
  - Icam1
  - Foxp3
  - Il10
  - S1pr1
  - Syt1
  - Nfkb1
  - Bax
  - TJP1
  - GJA1
  - HGF
  - IL6
  - SOS1
  - FGF2
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - VCAM1
  - MAPK3
  - MAPK1
  - TGFB1
  - TGFB2
  - TGFB3
  - ACTA1
  - CXCR4
  - AMPD1
  - MXD1
  - MMP1
  - MMP2
  - MMP3
  - MMP7
  - MMP8
  - MMP9
  - MMP10
  - MMP11
  - MMP12
  - MMP13
  - MMP14
  - MMP15
  - MMP16
  - MMP17
  - MMP19
  - MMP20
  - MMP21
  - MMP23B
  - MMP24
  - MMP25
  - MMP26
  - MMP27
  - MMP28
  - CXCL12
  - NELFCD
  - IL13
  - IL17A
  - TNF
  - ICAM1
  - FOXP3
  - IL10
  - S1PR1
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - NFKB1
  - SOD1
  - SOD2
  - SOD3
  - BAX
  - Gja3
  - Met
  - Ltbp1
  - Acta2
  - Mxd1
  - Hand1
  - Nelfcd
  - Rela
  - Gorasp1
  - Nkx3-1
  - gja1b
  - fgf2
  - vegfaa
  - vcam1b
  - mapk3
  - cxcr4b
  - smad5
  - mxd3
  - cxcl12a
  - il13
  - il6
  - tnfb
  - foxp3a
  - il10
  - s1pr1
  - s1pr5a
  - rela
  - baxa
---
